anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The most common complication during esophagogastroduodenoscopy (EGD) under sedation is hypoxemia. There is a scarcity of indicators to predict the risk of hypoxemia during EGD under sedation accurately. The width of the lower tongue base measured by ultrasound (US) is considered to be a significant predictor of the presence and severity of obstructive sleepapnea syndrome (OSAS), which develops hypoxemia by a similar mechanism to EGD under sedation. This study aimed to observe its ability to predict hypoxemia during EGD under sedation.Material and methodsː Adult patients undergoing EGD under sedation at our hospital after assessment in the anesthesia clinic were enrolled in the study. The width of the lower tongue base was measured as the distance between the lingual arteries (DLA) on both sides of the inferior lateral margin of the tongue by US. The primary outcome was hypoxemia defined as the SpO2 <90% for longer than 10 seconds during EGD under sedation. ResultsːA total of 304 patients were successfully included, and hypoxemia was reported in 32 patients (10.5%). The DLA prediction criterion for hypoxemia was >31 mm. The DLA was correlated with hypoxemia (Spearman correlation coefficient, 0.455; p<0.001) and owned the highest area under the receiver operating characteristic curve (0.927; 99% CI, 0.891 to 0.953, compared with that of the other predictors, p< 0.001) with hypoxemia.Conclusionsː The width of the lower tongue base, measured as the DLA by US examination can be used to effectively predict the risk of hypoxemia during EGD under sedation.
Coupling proteins that make strong protein-protein interactions equipped with cell penetrating peptides (CPPs) provide a convenient and powerful method to perturb cell interiors; there are many potential payloads and a broad palette of selectively membrane permeable probes. In a preferred embodiment, the coupling protein will be calmodulin or a related calcium binding protein. In a preferred embodiment, the CPP will be TAT or another CPP. In a preferred embodiment, the coupling protein will release its payload after targeting to an interior compartment. Cargo proteins can be purified by affinity methods using the same tag that allows binding by the adaptor, enabling an integrated approach with ‘gains in both function and safety. Access to cell interior compartments has potential applications in research, diagnostics, and therapeutics.
BACKGROUND AND OBJECTIVES: Although coordinated care (CC) seeks to improve patient experiences and ultimately health outcomes, evidence from empirical research on the impacts of CC is mixed. This study examined the relationship between CC and healthcare outcomes over a 4-year period among older adults with multiple chronic conditions.
RESEARCH DESIGN AND METHODS: This observational cohort study is based on data from the 2016-2020 Health and Retirement Study. Analysis is limited to respondents with 2+ chronic conditions who completed an experimental module on CC in 2016 (n = 906). Three domains of CC were assessed: perceptions, informal (family/friends) and formal (healthcare staff) tangible support, and technical support (using a "patient portal"). The longitudinal relationship between CC and health (e.g., pain, functioning, and self-rated health [SRH]) and healthcare (e.g., doctor visits, hospitalization, and care satisfaction) outcomes was investigated using mixed-effects models.
RESULTS: Better perceptions of CC were associated with lower odds of ADL limitations (Odds ratio [OR] = 0.91; 95% CI = 0.84-0.99) and greater satisfaction with care (B = 0.04, 95% CI = 0.02-0.06). Receipt of more informal tangible support was associated with 1.34 higher odds of ADL limitations (95% CI = 1.19-1.51) and 1.74 higher odds of hospitalization (95% CI = 1.07-1.21). Use of technical support was associated with better SRH and greater satisfaction with care.
DISCUSSION AND IMPLICATIONS: The longitudinal relationship between CC and health is multifaceted. Although positive perceptions and more technical support have beneficial effects on health outcomes, higher utilization of tangible support may reflect a higher demand among older adults with more complex healthcare needs.
Subjects will received niraparib 200mg or 100mg alternate once daily and oral etoposide 50mg on day 1-20 of a 30-day cycle. Oral etoposide was administered for a maximum of 6-8 cycles. Treatment was continued until disease progression, patient withdrawal or unacceptable toxic effects.
The experimental treatments include controls (clean air, irrelevant odor), blocking odors, cigarette smoke odor, and cigarette smoke odor mixed with blocking odors or irrelevant odor. To obtain cigarette smoke odor a 1 inch length of a 1R6F research cigarette is burned to completion in a sealed 5 gallon chamber fitted with septa. Using a syringe fit with a needle and filter, 60 mL aliquots of smoke odor are obtained. These smoke odor aliquots, along with blocking odors, are injected into odor sample bags fit with a septum and a valve that can be attached to the CPAP nose mask worn by each participating smoker. Participants open the valve, inhale once through the nose, close the valve, and then remove the bag from the mask before reporting odor pleasantness and the desire to smoke. A 2 - 3 min wait period is enforced between each odor presentation to prevent odor adaptation and to allow acute motivational effects to subside.

In a testing session a participant sniffs 4 concentrations of a mixture of 2 blocking odors, along with control odor samples. Presentation order is randomized. Each participant is assigned their own CPAP nose mask, and masks are disinfected after use. Participants also provide demographic (age, sex, ethnic and racial background) and smoking history information (cigarettes per day, preferred brand, age at onset, and time since last cigarette).
PURPOSE:To provide the titled medicinal preparation composed of a mixture containing a cellulose lower alkyl ether, polyacrylic acid, a foaming agent and a drug component, releasing the drug component slowly in the stomach and supplying the drug component at a concentration sufficiently high to attain the remedying effect for a long period. CONSTITUTION:The objective medicinal preparation can be produced preferably by mixing (A) 10pts. of a cellulose lower alkyl ether, (B) 0.1-1,000pts.wt. of polyacrylic acid or its salt and (C) 1-40pts.wt. (based on 10pts.wt. of A+B) of a foaming agent. The component A is preferably a compound having a viscosity of 3-10,000cps and 2% aqueous solution at 20 deg.C, and the foaming agent is a carbonate, a bicarbonate, etc. The agent can be retained in the stomach in suspending and floating granular state even if administered in the form of tablet, not to speak of powder and granule, and slowly releases the drug component. It can be produced easily.
School children with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) not receiving vaccine. Control group.
Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
A method and system are provided to report the findings of an expert's analysis of image data. The method and system are based on a reporting system that forms the basis of an image management system that can efficiently and systematically generate reports, facilitate data entry into searchable databases for data mining, and expedite billing and collections for the expert's services. The expert identifies a significant finding on an image and attaches a location-description code to the location of that finding in order to create a significant finding and an entry into a data base (410 and 412). Further descriptions of that finding, such as dimensional measurements, audio descriptions, 3D rendered snapshots, etc., may be automatically appended to the finding as secondary attributes of the finding within the database (414). At the end of the expert's evaluation ofthe image(s), the system sorts the findings in the database and presents the findings by prioritized categories. The expert edits and approves a multimedia report, which may be delivered to an Internet server for immediate access, archived in the database, sent by automated voice, fax or e-mail to an end-user, or any combination thereof (416, 418, 420 and 422).
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to anesthesiology and surgery. Install two drainage – one to the dome of the pleural cavity and one to the posterior pleural sinus. Pleura and intercostal muscles are sutured. After the suturing of the pleura and intercostal muscles, a plastic catheter with holes is installed over the entire length of the sutured wound surface of the intercostal muscles, its cannula is removed in the lateral edge of the wound, through which a local anesthetic is administered in combination with an antibacterial drug and a drug that improves microcirculation and repair every 6–8 hours for 7–10 days. End of the catheter without a cannula is fixed to the intercostal muscles with absorbable suture material, and a part of the catheter with a cannula is fixed by binding to the subcutaneous fat with absorbable suture material. After suturing the thoracic fascia and subcutaneous fat is established on the length of the entire stitched wound surface of the subcutaneous fat, the second plastic catheter with holes, its cannula is removed in the medial edge of the wound, through which a local anesthetic and a drug that improves microcirculation and repair are administered every 6–8 hours for 7–10 days. End of the catheter without a cannula is fixed to the subcutaneous fat with absorbable suture material, and a part of the catheter with a cannula is fixed by stitching to the skin with an absorbable suture material.EFFECT: method contributes to the effective postoperative anesthesia of the entire wound surface, improves microcirculation, repair, reduces the number of postoperative complications.1 cl, 1 ex, 2 dwg
In this session, the participant will smoke two-thirds of one inactive placebo cannabis cigarette (0% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
Epigenetic reprogramming plays a critical role in cancer progression of cancer, and N6-methyladenosine (m6A) is the most common RNA modification in eukaryotes. The purpose of this study was to explore the related modification mode of m6A regulator construction and evaluate the invasion and migration of thyroid cancer. Our results showed that m6A levels were significantly increased in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC) samples, which may have been induced by the down-regulation of demethylase fat mass and obesity-associated gene (FTO). Moreover, FTO inhibited PTC and ATC invasion and metastasis through the epithelial-to-mesenchymal transition (EMT) pathway in vivo and in vitro. Mechanistically, an m6A-mRNA epitranscriptomic microarray showed that Cadherin 12 (CDH12) is the key target gene mediated by FTO in an m6A-dependent manner. CDH12 promotes invasion and metastasis through the EMT pathway in thyroid cancer, both in vivo and in vitro. Furthermore, we found that insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is an important m6A reading protein, that regulates the stability of CDH12 mRNA and mediates EMT progression, thereby promoting the invasion and metastasis of PTC and ATC. Thus, FTO, IGF2BP2 and CDH12 may be effective therapeutic targets for PTC and ATC with significant invasion or distant metastasis. Schematic summary of FTO-IGF2BP2 axis in modulation of CDH12 mRNA m6A and upregulation of CDH12 expression in the invasion and metastasis of thyroid carcinoma.
PURPOSE:To obtain a remedy for periodontosis having controlled rate of release of the drug component corresponding to the change in the focus and suitable for the application to periodontal pocket or periodontal site, by mixing a substance effective as a remedy for periodontosis to a polymer soluble in water in a specific pH range and forming the mixture. CONSTITUTION:The objective remedy can be produced by mixing (A) a polymer soluble in water at an arbitrary pH between 4.0-7.6, e.g. (i) a copolymer of (meth)acrylic acid and their esters, (ii) a polysaccharide acetate or alkylated polysaccharide, (iii) an alkyl ether of carboxyalkylated polysaccharide and (iv) an organic dibasic acid ester of PVA or polyvinyl acetate with (B) a substance having remedying or preventive effect to periodontosis (e.g. antibacterial agent, plaque-dissolving agent, antiinframmatory agent, hemostatic agent, etc.) and forming the mixture in the form of sheet, film, rod, gel or ointment. The remedy is inserted, injected, pasted or applied to periodontal pocket or periodontal site.
During the Randomized Double-Blind Phase, participants will receive SIM 75 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
The goal of this study is to test a multilevel approach to reduce adverse consequences of the COVID-19 pandemic with disparate impacts on Latinx and Black immigrants and refugees by observing and implementing three nested levels of intervention: 1) an efficacious 6-month peer advocacy and mutual learning model (Refugee and Immigrant Well-being Project, RIWP); 2) engagement with community-based organizations (CBOs); and 3) structural policy changes expected to be enacted in response to the pandemic, such as a state disaster relief proposal for mixed status Latinx families and expanded statewide health insurance coverage. This community-based participatory research (CBPR) study builds on a long-standing collaboration with five community-based organizations (CBOs) that focus on mental health, education, legal issues, and system change efforts to improve the well-being of Latinx immigrants and African refugees. By including 240 Latinx immigrants and 60 African refugees recruited from CBO partners who are randomly assigned to treatment-as-usual CBO involvement or the RIWP intervention and a random sample comparison group of 900 Latinx immigrants, this mixed methods longitudinal waitlist control group design study with five time points over 28 months will test the effectiveness of the RIWP intervention and engagement with CBOs to reduce psychological distress, daily stressors, and economic precarity and increase protective factors (social support, critical awareness of/access to resources, English proficiency, cultural connectedness, and mental health service use). This study will also test the ability of the RIWP intervention and engagement with CBOs to increase access to the direct benefits of structural interventions (local/state relief-related policies) for Latinx and Black immigrants and refugees. Mechanisms of intervention effectiveness will be explored by testing mediating relationships between primary outcomes and protective factors. Investigators will also track local/state policy changes and obtain preliminary quantitative estimates of effects of these structural interventions on psychological distress, stressors, and economic precarity using propensity score matching. Qualitative interview data from a purposive subsample of participants and CBO staff will enable additional exploration of mechanisms of change, the effects of policy interventions on individuals, how CBOs contribute to enacting policies and helping people benefit from them, and the context of RIWP implementation at each site. This research is innovative and significant because it employs cutting-edge research design and intervention strategies to advance the science of multilevel mental health interventions that aim to understand and address underlying structural inequities and resulting mental health disparities that have been highlighted and exacerbated by the pandemic. Thus, this study will contribute not only to reducing the disparate adverse mental health, behavioral, and socioeconomic consequences of the COVID-19 pandemic but also to eliminating mental health disparities among Latinx and Black populations.
PURPOSE:To obtain the title substance obtained as an acid insoluble fraction containing lignin of phenolic high polymer compound extracted from a wooden material as a main ingredient, having high cation exchange ability, capable of absorbing Na ion and capable of continuously adding without impairing food characteristics. CONSTITUTION:The aimed substance obtained as an acid insoluble fraction containing lignin of phenolic high polymer compound extracted from a wooden material as a main ingredient. Furthermore, cacao or other plant body is directly used as a raw material or material obtained by subjecting the cacao or other plant body to physical treatment such as pulverizing, chemical treatment such as various kind of solvent extractions or biochemical treatment such as fermentation is used as a raw material and 40-98% concentrated sulfuric acid is added to the above-mentioned raw material at an amount of 2-10 times by vol. to hydrolyze the raw material and the hydrolyzate is filtered and cleaned to provide the aimed substance as the residue. The aimed substance has preferably physicochemical characteristics such as >=200 molecular weight, <=1% sugar content, 1.5-5. 5% nitrogen amount, <=10% fat content, <=10% ash content and 5-40% methoxy group number.
The invention discloses a nano silver anti-inflammatory gel for treating gynecologic inflammation and a preparation method thereof. The gynecologic inflammation is a common frequently-occurring disease; and an ideal effect cannot be easily obtained from the traditional therapeutic drug. 1000g of gel is prepared from 100-200 PPM of nano silver powder, 2-3g of camellia oil, 2-3g of eucalyptus oil, 0.002-0.008g of sodium dodecyl sulfate, 10-20g of propolis, 4-6g of carbopol, 4-6g of triethanolamine and the balance of pure water. The nano silver anti-inflammatory gel has excellent curative effect on pathogenic microorganism infective inflammation diseases such as gynecologic inflammation, cervicitis, or mixed infection. The gel disclosed by the invention is directly administered through vagina; and the drug directly achieves the focus of infection, and is explicit in targeting property, concise and convenient. The nano silver anti-inflammatory gel has strong inhibiting or killing roles on various pathogens such as gram positive bacteria, gram negative bacteria, mould, trichomonad and the like by experimental and clinical validation. The nano silver anti-inflammatory gel has good curative effect on colpitis, cervicitis, annexitis and pelvic inflammation caused by lactobacillus, mycete, candida albicans, HPV (human papillomavirus) and the like.
Vasogenic brain edema, a potentially life-threatening consequence following an acute ischemic stroke, is a major clinical problem. This research aims to explore the therapeutic benefits of nimodipine, a calcium channel blocker, in mitigating vasogenic cerebral edema and preserving blood-brain barrier (BBB) function in an ischemic stroke rat model. In this research, animals underwent the induction of ischemic stroke via a 60-min blockage of the middle cerebral artery and treated with a nonhypotensive dose of nimodipine (1 mg/kg/day) for a duration of five days. The wet/dry method was employed to identify cerebral edema, and the Evans blue dye extravasation technique was used to assess the permeability of the BBB. Furthermore, immunofluorescence staining was utilized to assess the protein expression levels of matrix metalloproteinase-9 (MMP-9) and intercellular adhesion molecule-1 (ICAM-1). The study also examined mitochondrial function by evaluating mitochondrial swelling, succinate dehydrogenase (SDH) activity, the collapse of mitochondrial membrane potential (MMP), and the generation of reactive oxygen species (ROS). Post-stroke administration of nimodipine led to a significant decrease in cerebral edema and maintained the integrity of the BBB. The protective effects observed were associated with a reduction in cell apoptosis as well as decreased expression of MMP-9 and ICAM-1. Furthermore, nimodipine was observed to reduce mitochondrial swelling and ROS levels while simultaneously restoring MMP and SDH activity. These results suggest that nimodipine may reduce cerebral edema and BBB breakdown caused by ischemia/reperfusion. This effect is potentially mediated through the reduction of MMP-9 and ICAM-1 levels and the enhancement of mitochondrial function.
Coronary artery disease (CAD) is the predominant cause of heart failure, a major cause of death and disability throughout the world. Although prognosis of patients with CAD has been greatly improved by advances in cardiovascular treatment, it is still the first cause of death in the USA. Treatment options for CAD include diet, exercise, medication, balloon angioplasty with or without stenting, atherectomy and bypass surgery. For many patients, however, the disease is diffuse and stenting or bypass surgery is not an option. A new strategy to treat these patients is to use gene therapy to induce new networks of new blood vessels to bypass the arterial system that is blocked, thus providing circulation to deliver oxygen needed by the tissue. By administering a gene coding for vascular endothelial growth factor (VEGF) to the myocardium, new networks of blood vessels can be created using the genetic material for VEGF. In experimental animal studies, VEGF is effective at treating ischemia of organs and is safe. The most direct method of transferring genes to myocardium is by injection under direct vision during a minimally invasive thoracic surgery. For the present study, the VEGF gene will be delivered to the myocardium using a modified adenovirus (Ad) as a carrier. The study is designed to test the safety and efficacy of AdVEGF-All6A+.
Inadequate Tumor Characterization and Other ER-Positive Pathology

Breast cancer may be heterogeneous within patients and across time. CERIANNA images ER and is not useful for imaging other receptors such as HER2 and PR. The uptake of fluoroestradiol F 18 is not specific for breast cancer and may occur in a variety of ER-positive tumors that arise outside of the breast, including from the uterus and ovaries. Do not use CERIANNA in lieu of biopsy when biopsy is indicated in patients with recurrent or metastatic breast cancer.

False Negative CERIANNA Scan

A negative CERIANNA scan does not rule out ER-positive breast cancer [see Clinical Studies (14)]. Pathology or clinical characteristics that suggest a patient may benefit from systemic hormone therapy should take precedence over a discordant negative CERIANNA scan.